Welcome to the e-CCO Library!

P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Visuri*1, C. Eriksson1, E. Mårdberg1, O. Grip2, A. Gustavsson3, H. Hjortswang4,5, P. Karling6, S. Montgomery7,8,9, P. Myrelid4,10, O. Olén9,11,12, The SWIBREG Study Group1, J. F. Ludvigsson13,14, J. Halfvarson1

Created: Friday, 22 February 2019, 9:41 AM
P649: Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.C. Marini1, A. Gils2*, G. Shankar1, M. Peeters2, E. Brouwers2, P. van Iperen3, M. Le Bars4, G.S. Bevalander3, B. Sattin5, S. Sloan6

Created: Thursday, 21 February 2019, 9:14 AM
P649: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Carbery, I.(1)*;Lin, S.(2);Chanchlani, N.(2);Janjua, M.(2);Nice, R.(3);McDonald, T.J.(3);Bewshea, C.(4);Kennedy, N.A.(2);Ahmad, T.(2);Goodhand, J.R.(2);Selinger, C.P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wade K., Johnson H., Slinger K., Hovell C., Weaver S., McLaughlin S.

Created: Wednesday, 20 February 2019, 10:36 AM
P649: The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3);
Created: Friday, 11 February 2022, 3:56 PM
P650 Outcomes of endoscopic balloon dilation for luminal strictures in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Sarraj, M. Martinho, F. Bravo, E. Benz, P. Juillerat

Created: Thursday, 30 January 2020, 10:12 AM
P650: A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries
Year: 2021
Source: ECCO'21 Virtual
Authors: Mackenzie-Smith, L.(1);Wüthrich, H.(2);Laoun, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Zhu, B.L. Yang*

Created: Thursday, 21 February 2019, 9:14 AM
P650: IBD care from the patient perspective: The patient's turn
Year: 2022
Source: ECCO'22
Authors: Creemers, R.(1);van der Horst, D.(2);Raats, I.(3);Romberg-Camps, M.(1);Scherpenzeel, M.(2);van Bodegraven, A.(1);
Created: Friday, 11 February 2022, 3:56 PM
P650: Integrin expression patterns of patients with IBD treated with vedolizumab.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kokkotis, G.(1)*;Chalakatevaki, K.(1);Papathanasiou, E.(2);Tzanoudaki, M.(3);Kane, R.(3);Liatsis, M.(3);Zampeli, E.(2);Michopoulos, S.(2);Bamias, G.(1);
Created: Friday, 14 July 2023, 11:12 AM
P650: Mechanisms of Infliximab failure: the predictive role of MMP3
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Barberio*1, R. D'Incà2, S. Facchin3, M. Dalla Gasperina1, C. Fohom1, R. Cardin1, E. Savarino2, F. Zingone1

Created: Friday, 22 February 2019, 9:41 AM
P650: The prognostic impact of radical resection margins on the Recurrence of Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

van Amesfoort J.*1, Koens L.2, Bemelman W.1, Buskens C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P651 Does ambient temperature alter faecal calprotectin levels?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Cauchi1, J. Schembri2, M. Muscat2, P. Ellul2

Created: Thursday, 30 January 2020, 10:12 AM
P651: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P651: Barriers to clinical research in children with inflammatory bowel disease: the patients' perspective
Year: 2017
Source: ECCO '17 Barcelona
Authors:

El-Matary W., Deora V.

Created: Wednesday, 20 February 2019, 10:36 AM
P651: Comparison of Adverse Events of SARS-CoV-2 Vaccination between Patients with Inflammatory Bowel Disease and Healthcare Workers
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kim, J.(1)*;Sagong, M.(1);Lee, Y.J.(1);Kim, K.O.(2);Kim, E.S.(3);Kim, E.Y.(4);Jang, B.I.(2);
Created: Friday, 14 July 2023, 11:12 AM
P651: Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn’s disease: data from administrative databases in Tuscany, Italy
Year: 2021
Source: ECCO'21 Virtual
Authors: Bertani, L.(1);Ferraro, S.(2);Bartolini, C.(3);Convertino, I.(2);Giometto, S.(2);Cappello, E.(2);Valdiserra, G.(2);Tillati, S.(2);Blandizzi, C.(2);Lucenteforte, E.(2);Gini, R.(3);Tuccori, M.(2,4);Costa, F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P651: Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Winter*1, J. Izanec2, C. Busse2, Y. Wang3, J. Hyams4

Created: Friday, 22 February 2019, 9:41 AM
P651: Reliability of blood tests, neutrophil lymphocyte ratio (NLR) and Glasgow prognostic index (GPI) to evaluate the severity of the Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.O. Gur1*, S. Karaisli1, O.N. Dilek1, T. Acar1, S. Haciyanli1, B. Unsal2, M. Haciyanli1

Created: Thursday, 21 February 2019, 9:14 AM